APPENDIX. CONFERENCE DISCUSSION
Dr M. Hazekamp (Leiden, Netherlands): A difficult group, difficult management, and a high rate of previous intervention: 13 out of 16 patients and a similar high rate of associated procedures, 11 out of 16. And in terms of mortality, the results are perfect with only one late death, and that is really something to be proud of. You mentioned that there was Shone syndrome in, I think, one patient, hypoplastic left heart complex in two, six had the diagnosis of endocardial fibroelastosis, and about six patients also had mitral problems.
I want to specifically focus on this part of the population because you describe in your paper that only 40% of the patients were finally without any medication, so 60% were, as I read it here, on heart failure medication, on diuretics, beta blockers and ACE inhibitors. So I wonder, did you study the pulmonary hypertension on latest echo, or the diastolic behaviour of the left ventricle, because even if these patients are now after five years in validity class 1, one might imagine that some of them have the problem of a stiff, noncompliant left ventricle. And it is, of course, very difficult to decide whether you should go univentricular or biventricular, and a too-aggressive approach in this group of children may be a little bit dangerous. We are at this moment now studying our own Ross-Konno infants, and we certainly have had several patients we are looking at in retrospect where we are sorry that we did not go the univentricular way. So could you comment on that, please?
Dr Aszyk: 40%, not 60%, of our patients are still on medical therapy, cardiac medical therapy, of whom one is on ACE inhibitors and diuretics due to renal failure, not to heart failure. The left ventricular outcomes in our echo follow-up actually are pretty good. We had shortening fraction of 40% on average, and the function of the autograft was excellent. We did not see any diastolic restriction, diastolic impairment.
Dr Hazekamp: And there were no patients at last follow-up who had pulmonary hypertension whatsoever?
Dr Aszyk: There is one patient with pulmonary hypertension. She also had mitral valve problems, and had already developed pulmonary hypertension. Medical therapy to reduce pulmonary vascular resistance has been started, and at current follow-up she is New York Heart Association class II and already listed for transplant.
Dr V. Hraska (Sankt Augustin, Germany): But there was another patient who died with the same mechanism, so basically we had two with pulmonary hypertension. I think that should be clarified.
Dr Hazekamp: And then there is only one technical question that I would like to ask you. Did you go always through the aortic valve or through the open LVOT to resect this white membrane of endocardial fibroelastosis, or did you also use a mitral approach?
Dr Aszyk: No. Always aortic. Dr Hazekamp: Never necessary, okay. Dr V. Tsang (London, UK): I will make a very brief comment about the Ross-Konno. In my own experience, in the majority of the patients I could manage to do without the Konno component. In a lot of these patients, once the very fibrotic aortic valve is removed and the subaortic fibrotic area excised, I only need to do a partial septal myectomy within the LVOT onto which I can put the autograft. And, in a way, that would preserve the integrity of the right ventricle and the ventricular septum. . Five patients were below 1 month of age. There was no operative mortality, although some early morbidity was noted. Importantly, the authors documented an extremely gratifying outcome at a median follow-up of 6.2 years, especially for infants with no structural abnormality of the mitral valve. Aortic regurgitation was absent or trivial in all cases, with complete and sustained resolution of LVOTO, as well as preservation of ventricular function. This outcome is concordant with my personal Konno-Ross operation experience in neonates and infants operated over the past 15 years in the USA and Australia. My impression is that the experience (published and unpublished) of other groups would largely support the data presented herein [2] [3] [4] [5] [6] [7] . There are a few comments and observations that I would like to offer regarding the Konno-Ross operation in infancy:
(i) The name Konno-Ross operation itself may be misleading as this operation bears little technical resemblance to the Konno operation as initially described [8] . A pulmonary autograft in a small baby virtually always requires an annular and LVOT enlargement, but seldom requires prosthetic patch material [9] . (ii) Problems inherent in older patients (especially young adults) undergoing the Ross operation, such as root dilation and insidious acquisition of aortic insufficiency, may not be as prevalent in neonates and small children undergoing Konno-Ross operation [1, 5, 7, 10] . In many ways, the neonates constitute quite a different cohort. not be completely accounted for [3, 10] . This type of decision-making therefore needs further refinement. (vii) The technical aspects of the Konno-Ross operation have been simplified and standardized over the past decade, and I would consider it to be both teachable and reproducible. Certainly the surgical skills needed for the arterial switch, aortic root translocation etc. are similar to those required for the neonatal Konno-Ross operation. The commonly associated lesions (arch obstruction, mitral disease, endocardial fibroelastosis (EFE), multiple ventricular septal defects) do increase the complexity level, and it is therefore the neonates who remain at greatest risk. Application of other strategies does not necessarily address this problem. The immediate benefit of the Konno-Ross operation strategy in the anatomically suitable and critically ill neonate is undisputed, as competing strategies are neither as effective nor safer. The realquestion centres on expanding the indications to offer primary Konno-Ross operation to young infants who could be well palliated in the short term with other strategies. The favourable longer-term follow-up data presented by the Sankt Augustin group support this concept, and once again point out the continued challenge of mitral disease and EFE and their association.
